<?xml version="1.0" encoding="UTF-8"?>
<drugs xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://drugbank.ca" xs:schemaLocation="http://www.drugbank.ca/docs/drugbank.xsd" schemaVersion="1.4">
  <drug type="biotech" created="2005-06-13 07:24:05 -0600" updated="2012-02-13 17:42:20 -0700" version="3.0">
    <drugbank-id>DB00001</drugbank-id>
    <name>Lepirudin</name>
    <description>Lepirudin is identical to natural hirudin except for substitution of leucine for isoleucine at the N-terminal end of the molecule and the absence of a sulfate group on the tyrosine at position 63. It is produced via yeast cells.&#xD;
</description>
    <cas-number>120993-53-5</cas-number>
    <general-references># Smythe MA, Stephens JL, Koerber JM, Mattson JC: A comparison of lepirudin and argatroban outcomes. Clin Appl Thromb Hemost. 2005 Oct;11(4):371-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16244762&#xD;
# Tardy B, Lecompte T, Boelhen F, Tardy-Poncet B, Elalamy I, Morange P, Gruel Y, Wolf M, Francois D, Racadot E, Camarasa P, Blouch MT, Nguyen F, Doubine S, Dutrillaux F, Alhenc-Gelas M, Martin-Toutain I, Bauters A, Ffrench P, de Maistre E, Grunebaum L, Mouton C, Huisse MG, Gouault-Heilmann M, Lucke V: Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood. 2006 Sep 1;108(5):1492-6. Epub 2006 May 11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16690967&#xD;
# Lubenow N, Eichler P, Lietz T, Greinacher A: Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost. 2005 Nov;3(11):2428-36. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16241940&#xD;
# Askari AT, Lincoff AM: Antithrombotic Drug Therapy in Cardiovascular Disease. 2009 Oct; pp. 440&#x2013;. ISBN 9781603272346. "Google books":http://books.google.com/books?id=iadLoXoQkWEC&amp;pg=PA440. </general-references>
    <synthesis-reference></synthesis-reference>
    <indication>For the treatment of heparin-induced thrombocytopenia</indication>
    <pharmacology>Lepirudin is used to break up clots and to reduce thrombocytopenia. It binds to thrombin and prevents thrombus or clot formation. It is a highly potent, selective, and essentially irreversible inhibitor of thrombin and clot-bond thrombin. Lepirudin requires no cofactor for its anticoagulant action. Lepirudin is a recombinant form of hirudin, an endogenous anticoagulant found in medicinal leeches.</pharmacology>
    <mechanism-of-action>Lepirudin forms a stable non-covalent complex with alpha-thrombin, thereby abolishing its ability to cleave fibrinogen and initiate the clotting cascade. The inhibition of thrombin prevents the blood clotting cascade. </mechanism-of-action>
    <toxicity>In case of overdose (eg, suggested by excessively high aPTT values) the risk of bleeding is increased.</toxicity>
    <biotransformation>Lepirudin is thought to be metabolized by release of amino acids via catabolic hydrolysis of the parent drug. However, con-clusive data are not available. About 48% of the administration dose is excreted in the urine which consists of unchanged drug (35%) and other fragments of the parent drug.</biotransformation>
    <absorption>Bioavailability is 100% following injection.</absorption>
    <half-life>Approximately 1.3 hours</half-life>
    <protein-binding></protein-binding>
    <route-of-elimination>Lepirudin is thought to be metabolized by release of amino acids via catabolic hydrolysis of the parent drug. About 48% of the administration dose is excreted in the urine which consists of unchanged drug (35%) and other fragments of the parent drug.</route-of-elimination>
    <volume-of-distribution>* 12.2 L [Healthy young subjects (n = 18, age 18-60 years)]&#xD;
* 18.7 L [Healthy elderly subjects (n = 10, age 65-80 years)]&#xD;
* 18 L [Renally impaired patients (n = 16, creatinine clearance below 80 mL/min)]&#xD;
* 32.1 L [HIT patients (n = 73)]</volume-of-distribution>
    <clearance>* 164 ml/min [Healthy 18-60 yrs]&#xD;
* 139 ml/min [Healthy 65-80 yrs]&#xD;
* 61 ml/min [renal impaired]&#xD;
* 114 ml/min [HIT (Heparin-induced thrombocytopenia)]</clearance>
    <secondary-accession-numbers>
      <secondary-accession-number>BIOD00024</secondary-accession-number>
      <secondary-accession-number>BTD00024</secondary-accession-number>
    </secondary-accession-numbers>
    <groups>
      <group>approved</group>
    </groups>
    <taxonomy>
      <kingdom></kingdom>
      <substructures/>
    </taxonomy>
    <synonyms>
      <synonym>Hirudin variant-1</synonym>
    </synonyms>
    <salts/>
    <brands>
      <brand>Refludan</brand>
    </brands>
    <mixtures/>
    <packagers>
      <packager>
        <name>Bayer Healthcare</name>
        <url>http://www.bayerhealthcare.com</url>
      </packager>
      <packager>
        <name>Berlex Labs</name>
        <url>http://www.berlex.com</url>
      </packager>
    </packagers>
    <manufacturers>
      <manufacturer generic="false">Bayer healthcare pharmaceuticals inc</manufacturer>
    </manufacturers>
    <prices>
      <price>
        <description>Refludan 50 mg vial</description>
        <cost currency="USD">273.19</cost>
        <unit>vial</unit>
      </price>
    </prices>
    <categories>
      <category>Anticoagulants</category>
      <category>Antithrombotic Agents</category>
      <category>Fibrinolytic Agents</category>
    </categories>
    <affected-organisms>
      <affected-organism>Humans and other mammals</affected-organism>
    </affected-organisms>
    <dosages>
      <dosage>
        <form>Powder, for solution</form>
        <route>Intravenous</route>
        <strength></strength>
      </dosage>
    </dosages>
    <atc-codes>
      <atc-code>B01AE02</atc-code>
    </atc-codes>
    <ahfs-codes>
      <ahfs-code>20:12.04.12</ahfs-code>
    </ahfs-codes>
    <patents>
      <patent>
        <number>5180668</number>
        <country>United States</country>
        <approved>1993-01-19</approved>
        <expires>2010-01-19</expires>
      </patent>
      <patent>
        <number>1339104</number>
        <country>Canada</country>
        <approved>1997-07-29</approved>
        <expires>2014-07-29</expires>
      </patent>
    </patents>
    <food-interactions/>
    <drug-interactions>
      <drug-interaction>
        <drug>DB01381</drug>
        <name>Ginkgo biloba</name>
        <description>Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.</description>
      </drug-interaction>
      <drug-interaction>
        <drug>DB00374</drug>
        <name>Treprostinil</name>
        <description>The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Lepirudin. Monitor for increased bleeding during concomitant thearpy. </description>
      </drug-interaction>
    </drug-interactions>
    <protein-sequences>
      <protein-sequence>
        <header>DB00001 sequence</header>
        <chain>LVYTDCTESGQNLCLCEGSNVCGQGNKCILGSDGEKNQCVTGEGTPKPQSHNDGDFEEIPEEYLQ</chain>
      </protein-sequence>
    </protein-sequences>
    <experimental-properties>
      <property>
        <kind>logP/hydrophobicity</kind>
        <value>-0.777</value>
        <source></source>
      </property>
      <property>
        <kind>Molecular Weight</kind>
        <value>6963.4250</value>
        <source></source>
      </property>
      <property>
        <kind>Molecular Formula</kind>
        <value>C287H440N80O110S6</value>
        <source></source>
      </property>
    </experimental-properties>
    <external-identifiers>
      <external-identifier>
        <resource>Drugs Product Database (DPD)</resource>
        <identifier>2240996</identifier>
      </external-identifier>
      <external-identifier>
        <resource>National Drug Code Directory</resource>
        <identifier>50419-150-57</identifier>
      </external-identifier>
      <external-identifier>
        <resource>PharmGKB</resource>
        <identifier>PA450195</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P01050</identifier>
      </external-identifier>
    </external-identifiers>
    <external-links>
      <external-link>
        <resource>Wikipedia</resource>
        <url>http://en.wikipedia.org/wiki/Lepirudin</url>
      </external-link>
      <external-link>
        <resource>RxList</resource>
        <url>http://www.rxlist.com/cgi/generic/lepirudin.htm</url>
      </external-link>
      <external-link>
        <resource>Drugs.com</resource>
        <url>http://www.drugs.com/cdi/lepirudin.html</url>
      </external-link>
    </external-links>
    <targets>
      <target partner="54">
        <actions>
          <action>inhibitor</action>
        </actions>
        <references># Turpie AG: Anticoagulants in acute coronary syndromes. Am J Cardiol. 1999 Sep 2;84(5A):2M-6M. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10505536&#xD;
# Warkentin TE: Venous thromboembolism in heparin-induced thrombocytopenia. Curr Opin Pulm Med. 2000 Jul;6(4):343-51. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10912644&#xD;
# Eriksson BI: New therapeutic options in deep vein thrombosis prophylaxis. Semin Hematol. 2000 Jul;37(3 Suppl 5):7-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11055889&#xD;
# Fabrizio MC: Use of ecarin clotting time (ECT) with lepirudin therapy in heparin-induced thrombocytopenia and cardiopulmonary bypass. J Extra Corpor Technol. 2001 May;33(2):117-25. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11467439&#xD;
# Szaba FM, Smiley ST: Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood. 2002 Feb 1;99(3):1053-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11807012&#xD;
# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
        <known-action>yes</known-action>
      </target>
    </targets>
    <enzymes/>
    <transporters/>
    <carriers/>
  </drug>
  <drug type="biotech" created="2005-06-13 07:24:05 -0600" updated="2011-07-31 23:04:49 -0600" version="3.0">
    <drugbank-id>DB00002</drugbank-id>
    <name>Cetuximab</name>
    <description>Epidermal growth factor receptor binding FAB. Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions.</description>
    <cas-number>205923-56-4</cas-number>
    <general-references></general-references>
    <synthesis-reference></synthesis-reference>
    <indication>For treatment of EGFR-expressing metastatic colorectal cancer in patients who are refractory to other irinotecan-based chemotherapy regimens. Cetuximab is also indicated for treatment of squamous cell carcinoma of the head and neck in conjucntion with radiation therapy.</indication>
    <pharmacology>Used in the treatment of colorectal cancer, cetuximab binds specifically to the epidermal growth factor receptor (EGFr, HER1, c-ErbB-1) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor&#x2013;alpha. Binding of cetuximab to the EGFr blocks phosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, decreased matrix metalloproteinase secretion and reduced vascular endothelial growth factor production.</pharmacology>
    <mechanism-of-action>Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.</mechanism-of-action>
    <toxicity>Single doses of cetuximab higher than 500 mg/m&lt;sup&gt;2&lt;/sup&gt; have not been tested. There is no experience with overdosage in human clinical trials.&#xD;
&#xD;
</toxicity>
    <biotransformation></biotransformation>
    <absorption></absorption>
    <half-life>114 hrs</half-life>
    <protein-binding></protein-binding>
    <route-of-elimination></route-of-elimination>
    <volume-of-distribution></volume-of-distribution>
    <clearance></clearance>
    <secondary-accession-numbers>
      <secondary-accession-number>BIOD00071</secondary-accession-number>
      <secondary-accession-number>BTD00071</secondary-accession-number>
    </secondary-accession-numbers>
    <groups>
      <group>approved</group>
    </groups>
    <taxonomy>
      <kingdom></kingdom>
      <substructures/>
    </taxonomy>
    <synonyms>
      <synonym>Anti EGFR</synonym>
      <synonym>IMC-C225</synonym>
    </synonyms>
    <salts/>
    <brands>
      <brand>Erbitux</brand>
    </brands>
    <mixtures/>
    <packagers>
      <packager>
        <name>Cardinal Health</name>
        <url>http://www.cardinal.com</url>
      </packager>
      <packager>
        <name>Catalent Pharma Solutions</name>
        <url>http://www.catalent.com</url>
      </packager>
      <packager>
        <name>ImClone Systems Inc.</name>
        <url>http://www.imclone.com</url>
      </packager>
      <packager>
        <name>Oso Biopharmaceuticals Manufacturing LLC</name>
        <url></url>
      </packager>
    </packagers>
    <manufacturers/>
    <prices/>
    <categories>
      <category>Antineoplastic Agents</category>
    </categories>
    <affected-organisms>
      <affected-organism>Humans and other mammals</affected-organism>
    </affected-organisms>
    <dosages>
      <dosage>
        <form>Solution</form>
        <route>Intravenous</route>
        <strength></strength>
      </dosage>
    </dosages>
    <atc-codes>
      <atc-code>L01XC06</atc-code>
    </atc-codes>
    <ahfs-codes/>
    <patents>
      <patent>
        <number>1340417</number>
        <country>Canada</country>
        <approved>1999-03-02</approved>
        <expires>2016-03-02</expires>
      </patent>
    </patents>
    <food-interactions/>
    <drug-interactions/>
    <protein-sequences>
      <protein-sequence>
        <header>Anti-EGFR heavy chain 1</header>
        <chain>QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</chain>
      </protein-sequence>
      <protein-sequence>
        <header>Anti-EGFR light chain 1</header>
        <chain>DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGA</chain>
      </protein-sequence>
      <protein-sequence>
        <header>Anti-EGFR heavy chain 2</header>
        <chain>QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</chain>
      </protein-sequence>
      <protein-sequence>
        <header>Anti-EGFR light chain 2</header>
        <chain>DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGA</chain>
      </protein-sequence>
    </protein-sequences>
    <experimental-properties>
      <property>
        <kind>logP/hydrophobicity</kind>
        <value>-0.413</value>
        <source></source>
      </property>
      <property>
        <kind>Molecular Weight</kind>
        <value>145781.6000</value>
        <source></source>
      </property>
      <property>
        <kind>Molecular Formula</kind>
        <value>C6484H10042N1732O2023S36</value>
        <source></source>
      </property>
    </experimental-properties>
    <external-identifiers>
      <external-identifier>
        <resource>National Drug Code Directory</resource>
        <identifier>66733-948-23</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank</resource>
        <identifier>J00228</identifier>
      </external-identifier>
      <external-identifier>
        <resource>PharmGKB</resource>
        <identifier>PA10040</identifier>
      </external-identifier>
    </external-identifiers>
    <external-links>
      <external-link>
        <resource>Wikipedia</resource>
        <url>http://en.wikipedia.org/wiki/Cetuximab</url>
      </external-link>
      <external-link>
        <resource>RxList</resource>
        <url>http://www.rxlist.com/cgi/generic3/erbitux.htm</url>
      </external-link>
      <external-link>
        <resource>Drugs.com</resource>
        <url>http://www.drugs.com/cdi/cetuximab.html</url>
      </external-link>
    </external-links>
    <targets>
      <target position="1" partner="844">
        <actions>
          <action>antagonist</action>
        </actions>
        <references># Hosokawa N, Yamamoto S, Uehara Y, Hori M, Tsuchiya KS: Effect of thiazinotrienomycin B, an ansamycin antibiotic, on the function of epidermal growth factor receptor in human stomach tumor cells. J Antibiot (Tokyo). 1999 May;52(5):485-90. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10480573&#xD;
# Wakita H, Takigawa M: Activation of epidermal growth factor receptor promotes late terminal differentiation of cell-matrix interaction-disrupted keratinocytes. J Biol Chem. 1999 Dec 24;274(52):37285-91. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10601294&#xD;
# Suwa T, Ueda M, Jinno H, Ozawa S, Kitagawa Y, Ando N, Kitajima M: Epidermal growth factor receptor-dependent cytotoxic effect of anti-EGFR antibody-ribonuclease conjugate on human cancer cells. Anticancer Res. 1999 Sep-Oct;19(5B):4161-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10628369&#xD;
# Burke P, Schooler K, Wiley HS: Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. Mol Biol Cell. 2001 Jun;12(6):1897-910. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11408594&#xD;
# Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J, Kerbel RS: Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. 2001 Jul 1;61(13):5090-101. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11431346&#xD;
# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
        <known-action>yes</known-action>
      </target>
      <target position="2" partner="1102">
        <actions/>
        <references># Snyder LC, Astsaturov I, Weiner LM: Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer. Clin Colorectal Cancer. 2005 Nov;5 Suppl 2:S71-80. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16336752</references>
        <known-action>unknown</known-action>
      </target>
      <target position="3" partner="3814">
        <actions/>
        <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#xD;
# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
        <known-action>unknown</known-action>
      </target>
      <target position="4" partner="3815">
        <actions/>
        <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#xD;
# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
        <known-action>unknown</known-action>
      </target>
      <target position="5" partner="3816">
        <actions/>
        <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#xD;
# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
        <known-action>unknown</known-action>
      </target>
      <target position="6" partner="3817">
        <actions/>
        <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#xD;
# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
        <known-action>unknown</known-action>
      </target>
      <target position="7" partner="3818">
        <actions/>
        <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#xD;
# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423&#xD;
# Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007 Aug 20;25(24):3712-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17704420</references>
        <known-action>unknown</known-action>
      </target>
      <target position="8" partner="2782">
        <actions/>
        <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#xD;
# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
        <known-action>unknown</known-action>
      </target>
      <target position="9" partner="784">
        <actions/>
        <references># Negri DR, Tosi E, Valota O, Ferrini S, Cambiaggi A, Sforzini S, Silvani A, Ruffini PA, Colnaghi MI, Canevari S: In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody. Br J Cancer. 1995 Oct;72(4):928-33. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7547242</references>
        <known-action>unknown</known-action>
      </target>
      <target position="10" partner="3819">
        <actions/>
        <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#xD;
# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423&#xD;
# Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007 Aug 20;25(24):3712-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17704420</references>
        <known-action>unknown</known-action>
      </target>
      <target position="11" partner="3820">
        <actions/>
        <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#xD;
# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
        <known-action>unknown</known-action>
      </target>
      <target position="12" partner="3821">
        <actions/>
        <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#xD;
# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
        <known-action>unknown</known-action>
      </target>
    </targets>
    <enzymes/>
    <transporters/>
    <carriers/>
  </drug>
  <drug type="biotech" created="2005-06-13 07:24:05 -0600" updated="2010-09-29 14:34:47 -0600" version="3.0">
    <drugbank-id>DB00003</drugbank-id>
    <name>Dornase Alfa</name>
    <description>Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology. The 260-amino acid sequence of dornase alfa is identical to the endogenous human enzyme. Dornase alfa cleaves extracellular DNA to 5&#xB4;-phosphodinucleotide and 5&#xB4;-phosphooligonucleotide end products without affecting intracellular DNA. In individuals with cystic fibrosis, extracellular DNA, which is an extremely viscous anion, is released by degenerating leukocytes that accumulate during inflammatory responses to infections. Enzymatic breakdown of this extracellular DNA appears to reduce sputum viscosity and viscoelasticity. </description>
    <cas-number>9003-98-9</cas-number>
    <general-references># Cramer GW, Bosso JA: The role of dornase alfa in the treatment of cystic fibrosis. Ann Pharmacother. 1996 Jun;30(6):656-61. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8792953 &#xD;
# Jones AP, Wallis C: Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev. 2010 Mar 17;3:CD001127. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20238314 &#xD;
# Riethmueller J, Kumpf M, Borth-Bruhns T, Brehm W, Wiskirchen J, Sieverding L, Ankele C, Hofbeck M, Baden W: Clinical and in vitro effect of dornase alfa in mechanically ventilated pediatric non-cystic fibrosis patients with atelectases. Cell Physiol Biochem. 2009;23(1-3):205-10. Epub 2009 Feb 18. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19255515 &#xD;
</general-references>
    <synthesis-reference></synthesis-reference>
    <indication>Used as adjunct therapy in the treatment of cystic fibrosis. </indication>
    <pharmacology>Cystic fibrosis (CF) is a disease characterized by the retention of viscous purulent secretions in the airways. These thick secretions contribute both to reduced pulmonary function and to frequent pulmonary infection. Purulent pulmonary secretions of individuals with cystic fibrosis contain very high concentrations of extracellular DNA released by degenerating leukocytes that accumulate in response to these infections. Dornase alfa hydrolyzes the DNA in sputum of CF patients and reduces sputum viscosity and viscoelasticity. The enzyme does not appear to affect sputum in the absence of an inflammatory response to infection, nor does it affect the sputum of healthy individuals. </pharmacology>
    <mechanism-of-action>Dornase alfa is a biosynthetic form of human DNase I. The enzyme is involved in endonucleolytic cleavage of extracellular DNA to 5&#xB4;-phosphodinucleotide and 5&#xB4;-phosphooligonucleotide end products. It has no effect on intracellular DNA. Optimal activity is dependent on the presence of divalent cations such as calcium and magnesium. Extracellular DNA is a viscous anionic polymer and its breakdown appears to improve the viscosity and viscoelasticity of purulent sputum of individuals with CF. </mechanism-of-action>
    <toxicity>Adverse reactions occur at a frequency of &lt; 1/1000 and are usually mild and transient in nature. Reported adverse effects include chest pain (pleuritic/non-cardiac), fever, dyspepsia, voice alteration (hoarseness), pharyngitis, dyspnea, laryngitis, rhinitis, decreased lung function, rash, urticaria, and conjunctivitis. </toxicity>
    <biotransformation></biotransformation>
    <absorption>Systemic absorption undetectable following administration by inhalation. </absorption>
    <half-life></half-life>
    <protein-binding></protein-binding>
    <route-of-elimination></route-of-elimination>
    <volume-of-distribution></volume-of-distribution>
    <clearance></clearance>
    <secondary-accession-numbers>
      <secondary-accession-number>BIOD00001</secondary-accession-number>
      <secondary-accession-number>BTD00001</secondary-accession-number>
    </secondary-accession-numbers>
    <groups>
      <group>approved</group>
    </groups>
    <taxonomy>
      <kingdom></kingdom>
      <substructures/>
    </taxonomy>
    <synonyms>
      <synonym>Deoxyribonuclease I</synonym>
      <synonym>Deoxyribonuclease-1 precursor</synonym>
      <synonym>DNase</synonym>
      <synonym>DNase I</synonym>
      <synonym>rhDNase</synonym>
    </synonyms>
    <salts/>
    <brands>
      <brand>Pulmozyme</brand>
      <brand>Viscozyme</brand>
    </brands>
    <mixtures>
      <mixture>
        <name>Cauterex</name>
        <ingredients>dornase alfa + fibrinolysin + gentamicin sulfate</ingredients>
      </mixture>
      <mixture>
        <name>Clorfibrase</name>
        <ingredients>dornase alfa + fibrinolysin + chloramphenicol</ingredients>
      </mixture>
      <mixture>
        <name>Elase</name>
        <ingredients>dornase alfa + fibrinolysin</ingredients>
      </mixture>
      <mixture>
        <name>Fibrabene</name>
        <ingredients>dornase alfa + fibrinolysin (bovine)</ingredients>
      </mixture>
      <mixture>
        <name>Fibrase SA</name>
        <ingredients>dornase alfa + fibrinolysin (bovine)</ingredients>
      </mixture>
      <mixture>
        <name>Fibrolan</name>
        <ingredients>dornase alfa + fibrinolysin (bovine)</ingredients>
      </mixture>
      <mixture>
        <name>Parkelase</name>
        <ingredients>dornase alfa + fibrinolysin</ingredients>
      </mixture>
      <mixture>
        <name>Ridasa</name>
        <ingredients>dornase alfa + ribonuclease</ingredients>
      </mixture>
    </mixtures>
    <packagers>
      <packager>
        <name>Cardinal Health</name>
        <url>http://www.cardinal.com</url>
      </packager>
      <packager>
        <name>Catalent Pharma Solutions</name>
        <url>http://www.catalent.com</url>
      </packager>
      <packager>
        <name>F Hoffmann-La Roche Ltd.</name>
        <url>http://www.roche.com</url>
      </packager>
      <packager>
        <name>Genentech Inc.</name>
        <url>http://www.gene.com</url>
      </packager>
      <packager>
        <name>Meda AB</name>
        <url>http://www.meda.se</url>
      </packager>
      <packager>
        <name>Medpointe Pharmaceuticals</name>
        <url></url>
      </packager>
    </packagers>
    <manufacturers>
      <manufacturer generic="false">Genentech, Inc</manufacturer>
    </manufacturers>
    <prices>
      <price>
        <description>Lufyllin 200 mg tablet</description>
        <cost currency="USD">3.21</cost>
        <unit>tablet</unit>
      </price>
      <price>
        <description>Lufyllin-gg tablet</description>
        <cost currency="USD">3.84</cost>
        <unit>tablet</unit>
      </price>
      <price>
        <description>Lufyllin-GG 200-200 mg tablet</description>
        <cost currency="USD">3.99</cost>
        <unit>tablet</unit>
      </price>
      <price>
        <description>Lufyllin-400 tablet</description>
        <cost currency="USD">4.62</cost>
        <unit>tablet</unit>
      </price>
      <price>
        <description>Lufyllin 400 mg tablet</description>
        <cost currency="USD">4.81</cost>
        <unit>tablet</unit>
      </price>
      <price>
        <description>Pulmozyme 1 mg/ml ampul</description>
        <cost currency="USD">37.05</cost>
        <unit>ml</unit>
      </price>
      <price>
        <description>Pulmozyme 1 mg/ml Solution 2.5ml Plastic Container</description>
        <cost currency="USD">77.06</cost>
        <unit>plastic</unit>
      </price>
      <price>
        <description>Lufyllin-GG 100-100 mg/15ml Elixir</description>
        <cost currency="USD">0.6</cost>
        <unit>ml</unit>
      </price>
    </prices>
    <categories>
      <category>Enzyme</category>
    </categories>
    <affected-organisms>
      <affected-organism>Humans and other mammals</affected-organism>
    </affected-organisms>
    <dosages>
      <dosage>
        <form>Solution</form>
        <route>Respiratory (inhalation)</route>
        <strength>1 mg/ml</strength>
      </dosage>
    </dosages>
    <atc-codes>
      <atc-code>R05CB13</atc-code>
    </atc-codes>
    <ahfs-codes>
      <ahfs-code>44:00</ahfs-code>
    </ahfs-codes>
    <patents>
      <patent>
        <number>2184581</number>
        <country>Canada</country>
        <approved>2005-02-22</approved>
        <expires>2015-02-28</expires>
      </patent>
      <patent>
        <number>2137237</number>
        <country>Canada</country>
        <approved>2004-10-26</approved>
        <expires>2013-05-28</expires>
      </patent>
    </patents>
    <food-interactions/>
    <drug-interactions/>
    <protein-sequences>
      <protein-sequence>
        <header>DB00003 sequence</header>
        <chain>LKIAAFNIQTFGETKMSNATLVSYIVQILSRYDIALVQEVRDSHLTAVGKLLDNLNQDAPDTYHYVVSEPLGRNSYKERYLFVYRPDQVSAVDSYYYDDGCEPCGNDTFNREPAIVRFFSRFTEVREFAIVPLHAAPGDAVAEIDALYDVYLDVQEKWGLEDVMLMGDFNAGCSYVRPSQWSSIRLWTSPTFQWLIPDSADTTATPTHCAYDRIVVAGMLLRGAVVPDSALPFNFQAAYGLSDQLAQAISDHYPVEVMLK</chain>
      </protein-sequence>
    </protein-sequences>
    <experimental-properties>
      <property>
        <kind>logP/hydrophobicity</kind>
        <value>-0.083</value>
        <source></source>
      </property>
      <property>
        <kind>Molecular Weight</kind>
        <value>29253.9000</value>
        <source></source>
      </property>
      <property>
        <kind>Molecular Formula</kind>
        <value>C1321H1999N339O396S9</value>
        <source></source>
      </property>
    </experimental-properties>
    <external-identifiers>
      <external-identifier>
        <resource>Drugs Product Database (DPD)</resource>
        <identifier>2046733</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank</resource>
        <identifier>M55983</identifier>
      </external-identifier>
      <external-identifier>
        <resource>PharmGKB</resource>
        <identifier>PA10318</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P24855</identifier>
      </external-identifier>
    </external-identifiers>
    <external-links>
      <external-link>
        <resource>Wikipedia</resource>
        <url>http://en.wikipedia.org/wiki/Dornase_alfa</url>
      </external-link>
      <external-link>
        <resource>RxList</resource>
        <url>http://www.rxlist.com/cgi/generic/pulmozyme.htm</url>
      </external-link>
      <external-link>
        <resource>Drugs.com</resource>
        <url>http://www.drugs.com/cdi/dornase-alfa.html</url>
      </external-link>
    </external-links>
    <targets>
      <target partner="874">
        <actions/>
        <references># Cramer GW, Bosso JA: The role of dornase alfa in the treatment of cystic fibrosis. Ann Pharmacother. 1996 Jun;30(6):656-61. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8792953</references>
        <known-action>yes</known-action>
      </target>
    </targets>
    <enzymes/>
    <transporters/>
    <carriers/>
  </drug>
  <drug type="biotech" created="2005-06-13 07:24:05 -0600" updated="2010-09-29 14:34:47 -0600" version="3.0">
    <drugbank-id>DB00004</drugbank-id>
    <name>Denileukin diftitox</name>
    <description>A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system.</description>
    <cas-number>173146-27-5</cas-number>
    <general-references># Turturro F: Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther. 2007 Jan;7(1):11-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17187516&#xD;
# Park M, Liu GT, Piltz-Seymour J, Wisda CL, Rook AH, Junkins-Hopkins JM, Nasta SD, Kim EJ: Vision loss following denileukin diftitox treatment: a case report of possible posterior ischemic optic neuropathy. Leuk Lymphoma. 2007 Apr;48(4):808-11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17454642</general-references>
    <synthesis-reference></synthesis-reference>
    <indication>For treatment of cutaneous T-cell lymphoma</indication>
    <pharmacology>Denileukin diftitox (Ontak) directs the cytocidal action of diphtheria toxin to cells which express the IL-2 receptor. The human IL-2 receptor exists in three forms, low (CD25), intermediate (CD122/CD132) and high (CD25/CD122/CD132) affinity. Malignant cells expressing one or more of the subunits of the IL-2 receptor are found in certain leukemias and lymphomas including cutaneous T-cell lymphoma (CTCL). Ontak interacts with the high affinity IL-2 receptor on the cell surface and inhibits cellular protein synthesis, resulting in cell death within hours.</pharmacology>
    <mechanism-of-action>Denileukin diftitox binds to the high-affinity IL-2 receptor complex. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes. The diphtheria toxin associated with Ontak then selectively kills the IL-2 bearing cells.</mechanism-of-action>
    <toxicity></toxicity>
    <biotransformation></biotransformation>
    <absorption></absorption>
    <half-life>70-80 min</half-life>
    <protein-binding></protein-binding>
    <route-of-elimination></route-of-elimination>
    <volume-of-distribution>* 0.06 to 0.09 L/kg</volume-of-distribution>
    <clearance>* 0.6 - 2.0 mL/min/kg [Lymphoma]</clearance>
    <secondary-accession-numbers>
      <secondary-accession-number>BIOD00084</secondary-accession-number>
      <secondary-accession-number>BTD00084</secondary-accession-number>
    </secondary-accession-numbers>
    <groups>
      <group>approved</group>
    </groups>
    <taxonomy>
      <kingdom>Organic</kingdom>
      <substructures>
        <substructure class="true">Polypeptides</substructure>
      </substructures>
    </taxonomy>
    <synonyms>
      <synonym>Diphtheria toxin precursor</synonym>
      <synonym>DT</synonym>
      <synonym>NAD(+--diphthamide ADP- ribosyltransferase)</synonym>
    </synonyms>
    <salts/>
    <brands>
      <brand>Ontak</brand>
    </brands>
    <mixtures/>
    <packagers>
      <packager>
        <name>Eisai Inc.</name>
        <url>http://www.eisai.com</url>
      </packager>
      <packager>
        <name>Hollister-Stier Laboratories LLC</name>
        <url>http://www.hollisterstier.com</url>
      </packager>
      <packager>
        <name>Ligand Pharmaceuticals Inc.</name>
        <url>http://www.ligand.com</url>
      </packager>
    </packagers>
    <manufacturers/>
    <prices>
      <price>
        <description>Ontak 150 mcg/ml vial</description>
        <cost currency="USD">878.4</cost>
        <unit>ml</unit>
      </price>
    </prices>
    <categories>
      <category>Antineoplastic Agents</category>
    </categories>
    <affected-organisms>
      <affected-organism>Humans and other mammals</affected-organism>
    </affected-organisms>
    <dosages>
      <dosage>
        <form>Solution</form>
        <route>Intravenous</route>
        <strength></strength>
      </dosage>
    </dosages>
    <atc-codes>
      <atc-code>L01XX29</atc-code>
    </atc-codes>
    <ahfs-codes/>
    <patents/>
    <food-interactions/>
    <drug-interactions>
      <drug-interaction>
        <drug>DB00072</drug>
        <name>Trastuzumab</name>
        <description>Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.</description>
      </drug-interaction>
    </drug-interactions>
    <protein-sequences>
      <protein-sequence>
        <header>DB00004 sequence</header>
        <chain>MGADDVVDSSKSFVMENFSSYHGTKPGYVDSIQKGIQKPKSGTQGNYDDDWKGFYSTDNKYDAAGYSVDNENPLSGKAGGVVKVTYPGLTKVLALKVDNAETIKKELGLSLTEPLMEQVGTEEFIKRFGDGASRVVLSLPFAEGSSSVEYINNWEQAKALSVELEINFETRGKRGQDAMYEYMAQACAGNRVRRSVGSSLSCINLDWDVIRDKTKTKIESLKEHGPIKNKMSESPNKTVSEEKAKQYLEEFHQTALEHPELSELKTVTGTNPVFAGANYAAWAVNVAQVIDSETADNLEKTTAALSILPGIGSVMGIADGAVHHNTEEIVAQSIALSSLMVAQAIPLVGELVDIGFAAYNFVESIINLFQVVHNSYNRPAYSPGHKTHAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT</chain>
      </protein-sequence>
    </protein-sequences>
    <experimental-properties>
      <property>
        <kind>logP/hydrophobicity</kind>
        <value>-0.301</value>
        <source></source>
      </property>
      <property>
        <kind>Molecular Weight</kind>
        <value>57647.3000</value>
        <source></source>
      </property>
      <property>
        <kind>Molecular Formula</kind>
        <value>C2560H4042N678O799S17</value>
        <source></source>
      </property>
    </experimental-properties>
    <external-identifiers>
      <external-identifier>
        <resource>National Drug Code Directory</resource>
        <identifier>62856-603-01</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank</resource>
        <identifier>V01536</identifier>
      </external-identifier>
      <external-identifier>
        <resource>PharmGKB</resource>
        <identifier>PA10317</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P00587</identifier>
      </external-identifier>
    </external-identifiers>
    <external-links>
      <external-link>
        <resource>Wikipedia</resource>
        <url>http://en.wikipedia.org/wiki/Denileukin_diftitox</url>
      </external-link>
      <external-link>
        <resource>RxList</resource>
        <url>http://www.rxlist.com/cgi/generic2/denileukin.htm</url>
      </external-link>
      <external-link>
        <resource>Drugs.com</resource>
        <url>http://www.drugs.com/cdi/denileukin-diftitox.html</url>
      </external-link>
    </external-links>
    <targets>
      <target position="1" partner="724">
        <actions>
          <action>binder</action>
        </actions>
        <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284
# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423
# Kiyokawa T, Shirono K, Hattori T, Nishimura H, Yamaguchi K, Nichols JC, Strom TB, Murphy JR, Takatsuki K: Cytotoxicity of interleukin 2-toxin toward lymphocytes from patients with adult T-cell leukemia. Cancer Res. 1989 Jul 15;49(14):4042-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2786749
# Murphy JR, Kelley VE, Strom TB: Interleukin 2 toxin: a step toward selective immunomodulation. Am J Kidney Dis. 1988 Feb;11(2):159-62. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/3124610
# Duvic M, Talpur R: Optimizing denileukin diftitox (Ontak) therapy. Future Oncol. 2008 Aug;4(4):457-69. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18684057
# Turturro F: Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther. 2007 Jan;7(1):11-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17187516
# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
        <known-action>yes</known-action>
      </target>
      <target position="2" partner="717">
        <actions>
          <action>agonist</action>
        </actions>
        <references># Foss F, Demierre MF, DiVenuti G: A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2005 Jul 15;106(2):454-7. Epub 2005 Apr 5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15811959
# Foss F: Clinical experience with denileukin diftitox (ONTAK). Semin Oncol. 2006 Feb;33(1 Suppl 3):S11-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16516670
# Duvic M, Talpur R: Optimizing denileukin diftitox (Ontak) therapy. Future Oncol. 2008 Aug;4(4):457-69. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18684057
# Turturro F: Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther. 2007 Jan;7(1):11-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17187516
# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
        <known-action>yes</known-action>
      </target>
      <target position="3" partner="3823">
        <actions/>
        <references># Foss F, Demierre MF, DiVenuti G: A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2005 Jul 15;106(2):454-7. Epub 2005 Apr 5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15811959
# Foss F: Clinical experience with denileukin diftitox (ONTAK). Semin Oncol. 2006 Feb;33(1 Suppl 3):S11-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16516670
# Foss FM: DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology. Clin Lymphoma. 2000 Nov;1 Suppl 1:S27-31. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11707860</references>
        <known-action>unknown</known-action>
      </target>
    </targets>
    <enzymes/>
    <transporters/>
    <carriers/>
  </drug>
  <drug type="biotech" created="2005-06-13 07:24:05 -0600" updated="2011-04-15 15:28:58 -0600" version="3.0">
    <drugbank-id>DB00005</drugbank-id>
    <name>Etanercept</name>
    <description>Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids</description>
    <cas-number>185243-69-0</cas-number>
    <general-references></general-references>
    <synthesis-reference></synthesis-reference>
    <indication>For treatment of severe active rheumatoid arthritis in adults, severe juvenile idiopathic arthritis, ankylosing spondylitis, and severe plaque psoriasis.</indication>
    <pharmacology>Tumor necrosis factor TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Elevated levels of TNF are found in tissues and fluids of patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (AS), and plaque psoriasis. Etanercept binds specifically to tumor necrosis factor (TNF) and blocks its interaction with cell surface TNF receptors.</pharmacology>
    <mechanism-of-action>There are two distinct receptors for TNF (TNFRs), a 55 kilodalton protein (p55) and a 75 kilodalton protein (p75). The biological activity of TNF is dependent upon binding to either cell surface receptor (p75 or p55). Etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to two TNF molecules, thereby effectively removing them from circulation.</mechanism-of-action>
    <toxicity></toxicity>
    <biotransformation></biotransformation>
    <absorption></absorption>
    <half-life>102 +/- 30 hrs</half-life>
    <protein-binding></protein-binding>
    <route-of-elimination></route-of-elimination>
    <volume-of-distribution></volume-of-distribution>
    <clearance>* 160 +/- 80 mL/hr [RA patients]</clearance>
    <secondary-accession-numbers>
      <secondary-accession-number>BIOD00052</secondary-accession-number>
      <secondary-accession-number>BTD00052</secondary-accession-number>
    </secondary-accession-numbers>
    <groups>
      <group>approved</group>
    </groups>
    <taxonomy>
      <kingdom></kingdom>
      <substructures/>
    </taxonomy>
    <synonyms>
      <synonym>CD120b</synonym>
      <synonym>p75</synonym>
      <synonym>p80 TNF-alpha receptor</synonym>
      <synonym>TNF-R2</synonym>
      <synonym>Tumor necrosis factor receptor 2</synonym>
      <synonym>Tumor necrosis factor receptor superfamily member 1B precursor</synonym>
      <synonym>Tumor necrosis factor receptor type II</synonym>
    </synonyms>
    <salts/>
    <brands>
      <brand>Enbrel</brand>
      <brand>Enbrel (Immunex Corp)</brand>
      <brand>Enbrel Sureclick</brand>
    </brands>
    <mixtures/>
    <packagers>
      <packager>
        <name>Amgen Inc.</name>
        <url>http://www.amgen.com</url>
      </packager>
      <packager>
        <name>Boehringer Ingelheim Ltd.</name>
        <url>http://www.boehringer-ingelheim.com</url>
      </packager>
      <packager>
        <name>DSM Corp.</name>
        <url>http://www.dsm.com</url>
      </packager>
      <packager>
        <name>Immunex Corp.</name>
        <url></url>
      </packager>
      <packager>
        <name>Physicians Total Care Inc.</name>
        <url>http://www.physicianstotalcare.com</url>
      </packager>
      <packager>
        <name>Vetter Pharma Fertigung GmbH and Co. KG</name>
        <url>http://www.vetter-pharma.com</url>
      </packager>
    </packagers>
    <manufacturers>
      <manufacturer generic="false">Amgen Inc. + Wyeth + Takeda</manufacturer>
    </manufacturers>
    <prices>
      <price>
        <description>Enbrel 25 mg kit</description>
        <cost currency="USD">250.37</cost>
        <unit>each</unit>
      </price>
      <price>
        <description>Enbrel 50 mg/ml sureclick syr</description>
        <cost currency="USD">488.74</cost>
        <unit>syringe</unit>
      </price>
      <price>
        <description>Enbrel 4 25 mg Kit (1 Box = 1 Kit = Four 25 mg Vials)</description>
        <cost currency="USD">1016.57</cost>
        <unit>box</unit>
      </price>
      <price>
        <description>Enbrel (1 Box = 1 Kit = Four 50 mg Syringes) 3.92ml Box</description>
        <cost currency="USD">2033.14</cost>
        <unit>box</unit>
      </price>
      <price>
        <description>Enbrel SureClick (1 Box Contains Four 50 mg Prefilled Autoinjectors)</description>
        <cost currency="USD">2033.14</cost>
        <unit>box</unit>
      </price>
    </prices>
    <categories>
      <category>Antirheumatic Agents</category>
      <category>Immunomodulatory Agents</category>
    </categories>
    <affected-organisms>
      <affected-organism>Humans and other mammals</affected-organism>
    </affected-organisms>
    <dosages>
      <dosage>
        <form>Solution</form>
        <route>Subcutaneous</route>
        <strength></strength>
      </dosage>
    </dosages>
    <atc-codes>
      <atc-code>L04AA11</atc-code>
    </atc-codes>
    <ahfs-codes>
      <ahfs-code>92:00.00</ahfs-code>
    </ahfs-codes>
    <patents>
      <patent>
        <number>2476934</number>
        <country>Canada</country>
        <approved>2009-06-16</approved>
        <expires>2023-02-27</expires>
      </patent>
      <patent>
        <number>2123593</number>
        <country>Canada</country>
        <approved>2000-03-14</approved>
        <expires>2013-09-14</expires>
      </patent>
      <patent>
        <number>7276477</number>
        <country>United States</country>
        <approved>2007-10-02</approved>
        <expires>2024-07-29</expires>
      </patent>
      <patent>
        <number>36755</number>
        <country>United States</country>
        <approved>2000-06-27</approved>
        <expires>2012-10-23</expires>
      </patent>
    </patents>
    <food-interactions/>
    <drug-interactions>
      <drug-interaction>
        <drug>DB00072</drug>
        <name>Trastuzumab</name>
        <description>Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. </description>
      </drug-interaction>
    </drug-interactions>
    <protein-sequences>
      <protein-sequence>
        <header>DB00005 sequence</header>
        <chain>LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPQVKFNWYVDGVQVHNAKTKPREQQYNSTYRVVSVLTVLHQNWLDGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK</chain>
      </protein-sequence>
    </protein-sequences>
    <experimental-properties>
      <property>
        <kind>logP/hydrophobicity</kind>
        <value>-0.529</value>
        <source></source>
      </property>
      <property>
        <kind>Molecular Weight</kind>
        <value>51234.9000</value>
        <source></source>
      </property>
      <property>
        <kind>Molecular Formula</kind>
        <value>C2224H3475N621O698S36</value>
        <source></source>
      </property>
    </experimental-properties>
    <external-identifiers>
      <external-identifier>
        <resource>Drugs Product Database (DPD)</resource>
        <identifier>2242903</identifier>
      </external-identifier>
      <external-identifier>
        <resource>KEGG Compound</resource>
        <identifier>C07897</identifier>
      </external-identifier>
      <external-identifier>
        <resource>KEGG Drug</resource>
        <identifier>D00742</identifier>
      </external-identifier>
      <external-identifier>
        <resource>National Drug Code Directory</resource>
        <identifier>58406-455-04</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank</resource>
        <identifier>M32315</identifier>
      </external-identifier>
      <external-identifier>
        <resource>PharmGKB</resource>
        <identifier>PA449515</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P20333</identifier>
      </external-identifier>
    </external-identifiers>
    <external-links>
      <external-link>
        <resource>Wikipedia</resource>
        <url>http://en.wikipedia.org/wiki/Etanercept</url>
      </external-link>
      <external-link>
        <resource>RxList</resource>
        <url>http://www.rxlist.com/cgi/generic/etanercept.htm</url>
      </external-link>
      <external-link>
        <resource>Drugs.com</resource>
        <url>http://www.drugs.com/cdi/etanercept.html</url>
      </external-link>
    </external-links>
    <targets>
      <target position="1" partner="777">
        <actions>
          <action>antibody</action>
        </actions>
        <references># Park YC, Burkitt V, Villa AR, Tong L, Wu H: Structural basis for self-association and receptor recognition of human TRAF2. Nature. 1999 Apr 8;398(6727):533-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10206649&#xD;
# Sandborn WJ, Hanauer SB: Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999 May;5(2):119-33. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10338381&#xD;
# Grell M, Zimmermann G, Gottfried E, Chen CM, Grunwald U, Huang DC, Wu Lee YH, Durkop H, Engelmann H, Scheurich P, Wajant H, Strasser A: Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. EMBO J. 1999 Jun 1;18(11):3034-43. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10357816&#xD;
# Moreland LW: Inhibitors of tumor necrosis factor: new treatment options for rheumatoid arthritis. Cleve Clin J Med. 1999 Jun;66(6):367-74. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10375846&#xD;
# Calabrese LH: Rheumatoid arthritis and primary care: the case for early diagnosis and treatment. J Am Osteopath Assoc. 1999 Jun;99(6):313-21. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10405518&#xD;
# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
        <known-action>yes</known-action>
      </target>
      <target position="2" partner="1269">
        <actions/>
        <references># Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
        <known-action>unknown</known-action>
      </target>
      <target position="3" partner="784">
        <actions/>
        <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#xD;
# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
        <known-action>unknown</known-action>
      </target>
      <target position="4" partner="3818">
        <actions/>
        <references># Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, Wang J, Tiwari HK, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL Jr: The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 2004 Sep;50(9):2750-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15457442&#xD;
# Hughes LB, Criswell LA, Beasley TM, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL: Genetic risk factors for infection in patients with early rheumatoid arthritis. Genes Immun. 2004 Dec;5(8):641-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15526004</references>
        <known-action>unknown</known-action>
      </target>
      <target position="5" partner="3819">
        <actions/>
        <references># Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, Wang J, Tiwari HK, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL Jr: The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 2004 Sep;50(9):2750-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15457442&#xD;
# Hughes LB, Criswell LA, Beasley TM, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL: Genetic risk factors for infection in patients with early rheumatoid arthritis. Genes Immun. 2004 Dec;5(8):641-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15526004</references>
        <known-action>unknown</known-action>
      </target>
      <target position="6" partner="3820">
        <actions/>
        <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#xD;
# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
        <known-action>unknown</known-action>
      </target>
      <target position="7" partner="3821">
        <actions/>
        <references># Hart SP, Ross JA, Ross K, Haslett C, Dransfield I: Molecular characterization of the surface of apoptotic neutrophils: implications for functional downregulation and recognition by phagocytes. Cell Death Differ. 2000 May;7(5):493-503. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10800083&#xD;
# Ranheim EA, Kipps TJ: Tumor necrosis factor-alpha facilitates induction of CD80 (B7-1) and CD54 on human B cells by activated T cells: complex regulation by IL-4, IL-10, and CD40L. Cell Immunol. 1995 Apr 1;161(2):226-35. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7535196</references>
        <known-action>unknown</known-action>
      </target>
      <target position="8" partner="1789">
        <actions/>
        <references># Johnson CJ, Reilly KM, Murray KM: Etanercept in juvenile rheumatoid arthritis. Ann Pharmacother. 2001 Apr;35(4):464-71. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11302411&#xD;
# Pennica D, Lam VT, Mize NK, Weber RF, Lewis M, Fendly BM, Lipari MT, Goeddel DV: Biochemical properties of the 75-kDa tumor necrosis factor receptor. Characterization of ligand binding, internalization, and receptor phosphorylation. J Biol Chem. 1992 Oct 15;267(29):21172-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1328224&#xD;
# Gudbrandsdottir S, Larsen R, Sorensen LK, Nielsen S, Hansen MB, Svenson M, Bendtzen K, Muller K: TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2004 Jan-Feb;22(1):118-24. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15005015&#xD;
# Buch MH, Conaghan PG, Quinn MA, Bingham SJ, Veale D, Emery P: True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha? Ann Rheum Dis. 2004 Oct;63(10):1344-6. Epub 2004 Mar 19. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15033655&#xD;
# Kang CP, Lee KW, Yoo DH, Kang C, Bae SC: The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology (Oxford). 2005 Apr;44(4):547-52. Epub 2005 Feb 3. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15695296</references>
        <known-action>unknown</known-action>
      </target>
      <target position="9" partner="1102">
        <actions/>
        <references># Hart SP, Ross JA, Ross K, Haslett C, Dransfield I: Molecular characterization of the surface of apoptotic neutrophils: implications for functional downregulation and recognition by phagocytes. Cell Death Differ. 2000 May;7(5):493-503. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10800083&#xD;
# Ozgocmen S, Godekmerdan A, Ozkurt-Zengin F: Acute-phase response, clinical measures and disease activity in ankylosing spondylitis. Joint Bone Spine. 2007 May;74(3):249-53. Epub 2007 Mar 5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17387033&#xD;
# Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, Wang J, Tiwari HK, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL Jr: The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 2004 Sep;50(9):2750-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15457442&#xD;
# Hughes LB, Criswell LA, Beasley TM, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL: Genetic risk factors for infection in patients with early rheumatoid arthritis. Genes Immun. 2004 Dec;5(8):641-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15526004</references>
        <known-action>unknown</known-action>
      </target>
      <target position="10" partner="2782">
        <actions/>
        <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#xD;
# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
        <known-action>unknown</known-action>
      </target>
      <target position="11" partner="3814">
        <actions/>
        <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#xD;
# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
        <known-action>unknown</known-action>
      </target>
      <target position="12" partner="3815">
        <actions/>
        <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#xD;
# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
        <known-action>unknown</known-action>
      </target>
      <target position="13" partner="3816">
        <actions/>
        <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#xD;
# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
        <known-action>unknown</known-action>
      </target>
      <target position="14" partner="3817">
        <actions/>
        <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284&#xD;
# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
        <known-action>unknown</known-action>
      </target>
    </targets>
    <enzymes/>
    <transporters/>
    <carriers/>
  </drug>
  <drug type="biotech" created="2005-06-13 07:24:05 -0600" updated="2012-04-27 10:54:23 -0600" version="3.0">
    <drugbank-id>DB00006</drugbank-id>
    <name>Bivalirudin</name>
    <description>Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and blood pressure. </description>
    <cas-number>128270-60-0</cas-number>
    <general-references># Seybert AL, Coons JC, Zerumsky K: Treatment of heparin-induced thrombocytopenia: is there a role for bivalirudin? Pharmacotherapy. 2006 Feb;26(2):229-41. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16466327&#xD;
# Dager WE, Dougherty JA, Nguyen PH, Militello MA, Smythe MA: Heparin-induced thrombocytopenia: treatment options and special considerations. Pharmacotherapy. 2007 Apr;27(4):564-87. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17381384&#xD;
# Dang CH, Durkalski VL, Nappi JM: Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia. Pharmacotherapy. 2006 Apr;26(4):461-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16553503&#xD;
# Robson R: The use of bivalirudin in patients with renal impairment. J Invasive Cardiol. 2000 Dec;12 Suppl F:33F-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11156732&#xD;
# Van De Car DA, Rao SV, Ohman EM: Bivalirudin: a review of the pharmacology and clinical application. Expert Rev Cardiovasc Ther. 2010 Dec;8(12):1673-81. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/21108549&#xD;
# Shammas NW: Bivalirudin: pharmacology and clinical applications. Cardiovasc Drug Rev. 2005 Winter;23(4):345-60. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16614733&#xD;
# Gleason TG, Chengelis CP, Jackson CB, Lindstrom P: A 24-hour continuous infusion study of bivalirudin in the rat. Int J Toxicol. 2003 May-Jun;22(3):195-206. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12851152</general-references>
    <synthesis-reference></synthesis-reference>
    <indication>For treatment of heparin-induced thrombocytopenia and for the&#xD;
prevention of thrombosis. Bivalirudin is indicated for use in&#xD;
patients undergoing percutaneous coronary intervention (PCI), in&#xD;
patients at moderate to high risk acute coronary syndromes due to&#xD;
unstable angina or non-ST segment elevation in whom a PCI is planned.</indication>
    <pharmacology>Bivalirudin directly and reversibly inhibits thrombin by specifically binding both to the catalytic site and to the anion-binding exosite of circulating and clot-bound thrombin.  The action of bivalirudin is reversible because thrombin will slowly cleave the thrombin-bivalirudin bond which recovers the active site of thrombin. </pharmacology>
    <mechanism-of-action>Inhibits the action of thrombin by binding both to its catalytic site and to its anion-binding exosite. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross-linked framework which stabilizes the thrombus; thrombin also activates Factors V and VIII, promoting further thrombin generation, and activates platelets, stimulating aggregation and granule release.</mechanism-of-action>
    <toxicity>Based on a study by Gleason et al., the no-observed-adverse-effect level (NOAEL) for bivalirudin, administered to rats via intravenous infusion over a 24-hour period, was 2000 mg/kg/24 h.</toxicity>
    <biotransformation>80% proteolytic cleavage</biotransformation>
    <absorption>Following intravenous administration, bivalirudin exhibits linear&#xD;
pharmacokinetics .  The mean steady state concentration is 12.3 +/-&#xD;
1.7mcg/mL after administration of an intravenous bolus of 1mg/kg&#xD;
followd by a 2.5mg/kg/hr intravenous infusion given over 4 hours.</absorption>
    <half-life>* Normal renal function: 25 min (in normal conditions)&#xD;
* Creatinine clearance 10-29mL/min: 57min&#xD;
* Dialysis-dependant patients: 3.5h</half-life>
    <protein-binding>Other than thrombin and red blood cells, bivalirudin does not bind to&#xD;
plasma proteins.</protein-binding>
    <route-of-elimination>Bivalirudin is cleared from plasma by a combination of renal mechanisms (20%) and proteolytic cleavage.</route-of-elimination>
    <volume-of-distribution>0.2L/kg</volume-of-distribution>
    <clearance>* 3.4 mL/min/kg [Normal renal function]&#xD;
* 3.4 mL/min/kg [mild renal function]&#xD;
* 2.7 mL/min/kg [moderate renal function]&#xD;
* 2.8 mL/min/kg [severe renal function]&#xD;
* 1 mL/min/kg [Dialysis-dependent patients]</clearance>
    <secondary-accession-numbers>
      <secondary-accession-number>BIOD00076</secondary-accession-number>
      <secondary-accession-number>BTD00076</secondary-accession-number>
    </secondary-accession-numbers>
    <groups>
      <group>approved</group>
    </groups>
    <taxonomy>
      <kingdom></kingdom>
      <substructures/>
    </taxonomy>
    <synonyms/>
    <salts/>
    <brands>
      <brand>Angiomax</brand>
      <brand>Angiox</brand>
    </brands>
    <mixtures/>
    <packagers>
      <packager>
        <name>Ben Venue Laboratories Inc.</name>
        <url>http://www.benvenue.com</url>
      </packager>
      <packager>
        <name>Oryx Pharmaceuticals Inc.</name>
        <url></url>
      </packager>
      <packager>
        <name>Sepracor Pharmaceuticals Inc.</name>
        <url>http://www.sepracor.com</url>
      </packager>
      <packager>
        <name>The Medicines Co.</name>
        <url>http://www.themedicinescompany.com</url>
      </packager>
    </packagers>
    <manufacturers>
      <manufacturer generic="false">The medicines co</manufacturer>
    </manufacturers>
    <prices>
      <price>
        <description>Angiomax 250 mg vial</description>
        <cost currency="USD">780.0</cost>
        <unit>vial</unit>
      </price>
    </prices>
    <categories>
      <category>Anticoagulants</category>
      <category>Antithrombotic Agents</category>
    </categories>
    <affected-organisms>
      <affected-organism>Humans and other mammals</affected-organism>
    </affected-organisms>
    <dosages>
      <dosage>
        <form>Powder, for solution</form>
        <route>Intravenous</route>
        <strength>250mg</strength>
      </dosage>
    </dosages>
    <atc-codes>
      <atc-code>B01AE06</atc-code>
    </atc-codes>
    <ahfs-codes>
      <ahfs-code>20:12.04.12</ahfs-code>
    </ahfs-codes>
    <patents>
      <patent>
        <number>7582727</number>
        <country>United States</country>
        <approved>2009-01-27</approved>
        <expires>2029-01-27</expires>
      </patent>
      <patent>
        <number>5196404</number>
        <country>United States</country>
        <approved>1993-05-23</approved>
        <expires>2010-05-23</expires>
      </patent>
      <patent>
        <number>2065150</number>
        <country>Canada</country>
        <approved>1999-12-14</approved>
        <expires>2010-08-17</expires>
      </patent>
    </patents>
    <food-interactions>
      <food-interaction>Dan shen, dong quai, evening primrose oil, gingko, policosanol, willow bark</food-interaction>
      <food-interaction>Echinacea</food-interaction>
    </food-interactions>
    <drug-interactions>
      <drug-interaction>
        <drug>DB01609</drug>
        <name>Deferasirox</name>
        <description>Anticoagulants increase the risk for gastrointestinal ulceration/irritation and/or GI bleeding. If these two agents must be used, patients need to be closely monitored for signs and symptoms of GI toxicity.</description>
      </drug-interaction>
      <drug-interaction>
        <drug>DB00441</drug>
        <name>Gemcitabine</name>
        <description>Gemcitabine may enhance the adverse/toxic effect of Bleomycin. The risk of pulmonary toxicity may be increased. Use extreme caution if using gemcitabine and bleomycin in combination. Monitor for the development of pulmonary toxicity. </description>
      </drug-interaction>
      <drug-interaction>
        <drug>DB01381</drug>
        <name>Ginkgo biloba</name>
        <description>Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.</description>
      </drug-interaction>
      <drug-interaction>
        <drug>DB06228</drug>
        <name>Rivaroxaban</name>
        <description>Anticoagulants may enhance the anticoagulant effect of rivaroxaban. Avoid concurrent use of rivaroxaban with other anticoagulants whenever possible, other than during transition periods, due to the possible increased for bleeding. </description>
      </drug-interaction>
      <drug-interaction>
        <drug>DB00374</drug>
        <name>Treprostinil</name>
        <description>The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Bivalirudin. Monitor for increased bleeding during concomitant thearpy. </description>
      </drug-interaction>
    </drug-interactions>
    <protein-sequences>
      <protein-sequence>
        <header>DB00006 sequence</header>
        <chain>FPRPGGGGNGDFEEIPEEYL</chain>
      </protein-sequence>
    </protein-sequences>
    <experimental-properties>
      <property>
        <kind>logP/hydrophobicity</kind>
        <value>-0.985</value>
        <source></source>
      </property>
      <property>
        <kind>Molecular Weight</kind>
        <value>2180.2853</value>
        <source></source>
      </property>
      <property>
        <kind>Molecular Formula</kind>
        <value>C98H138N24O33</value>
        <source></source>
      </property>
    </experimental-properties>
    <external-identifiers>
      <external-identifier>
        <resource>Drugs Product Database (DPD)</resource>
        <identifier>2246533</identifier>
      </external-identifier>
      <external-identifier>
        <resource>National Drug Code Directory</resource>
        <identifier>65293-001-01</identifier>
      </external-identifier>
      <external-identifier>
        <resource>PharmGKB</resource>
        <identifier>PA10032</identifier>
      </external-identifier>
    </external-identifiers>
    <external-links>
      <external-link>
        <resource>Wikipedia</resource>
        <url>http://en.wikipedia.org/wiki/Bivalirudin</url>
      </external-link>
      <external-link>
        <resource>RxList</resource>
        <url>http://www.rxlist.com/cgi/generic/angiomax.htm</url>
      </external-link>
      <external-link>
        <resource>Drugs.com</resource>
        <url>http://www.drugs.com/cdi/bivalirudin.html</url>
      </external-link>
    </external-links>
    <targets>
      <target partner="54">
        <actions>
          <action>inhibitor</action>
        </actions>
        <references># Scatena R: Bivalirudin: a new generation antithrombotic drug. Expert Opin Investig Drugs. 2000 May;9(5):1119-27. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11060732&#xD;
# Bates ER: Bivalirudin for percutaneous coronary intervention and in acute coronary syndromes. Curr Cardiol Rep. 2001 Sep;3(5):348-54. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11504570&#xD;
# Gladwell TD: Bivalirudin: a direct thrombin inhibitor. Clin Ther. 2002 Jan;24(1):38-58. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11833835&#xD;
# Kleiman NS, Klem J, Fernandes LS, Rubin H, Challa S, Solomon S, Maresh K, Arora U, Klem E, Buergler J, Mathew S, Browning A, DeLao T: Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide. Am Heart J. 2002 Apr;143(4):585-93. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11923794&#xD;
# Carswell CI, Plosker GL: Bivalirudin: a review of its potential place in the management of acute coronary syndromes. Drugs. 2002;62(5):841-70. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11929334&#xD;
# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
        <known-action>yes</known-action>
      </target>
    </targets>
    <enzymes>
      <enzyme position="1" partner="1757">
        <actions>
          <action>inhibitor</action>
        </actions>
        <references># Rudolph V, Rudolph TK, Schopfer FJ, Bonacci G, Lau D, Szocs K, Klinke A, Meinertz T, Freeman BA, Baldus S: Bivalirudin decreases NO bioavailability by vascular immobilization of myeloperoxidase. J Pharmacol Exp Ther. 2008 Nov;327(2):324-31. Epub 2008 Aug 13. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18701766[</references>
      </enzyme>
    </enzymes>
    <transporters/>
    <carriers/>
  </drug>
  <drug type="biotech" created="2005-06-13 07:24:05 -0600" updated="2012-04-21 22:01:04 -0600" version="3.0">
    <drugbank-id>DB00007</drugbank-id>
    <name>Leuprolide</name>
    <description>Leuprolide belongs to the general class of drugs known as hormones or hormone antagonists. It is a synthetic 9 residue peptide analog of gonadotropin releasing hormone. Leuprolide is used to treat advanced prostate cancer. It is also used to treat uterine fibroids and endometriosis. Leuprolide is also under investigation for possible use in the treatment of mild to moderate Alzheimer's disease.</description>
    <cas-number>53714-56-0</cas-number>
    <general-references># Saleh FM, Niel T, Fishman MJ: Treatment of paraphilia in young adults with leuprolide acetate: a preliminary case report series. J Forensic Sci. 2004 Nov;49(6):1343-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15568711&#xD;
# Geier MR, Geier DA: The potential importance of steroids in the treatment of autistic spectrum disorders and other disorders involving mercury toxicity. Med Hypotheses. 2005;64(5):946-54. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15780490&#xD;
# Doraiswamy PM, Xiong GL: Pharmacological strategies for the prevention of Alzheimer's disease. Expert Opin Pharmacother. 2006 Jan;7(1):1-10. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16370917&#xD;
# Sequence Information "Link":http://www.freepatentsonline.com/EP1790656.html&#xD;
# "RxMed":http://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/CPS-%20Monographs/CPS-%20(General%20Monographs-%20L)/LUPRON%20DEPOT.html</general-references>
    <synthesis-reference></synthesis-reference>
    <indication>For treatment of prostate cancer, endometriosis, uterine fibroids and premature puberty</indication>
    <pharmacology>Used in the palliative treatment of advanced prostate cancer. Leuprolide is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis.</pharmacology>
    <mechanism-of-action>Leuprolide binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion.</mechanism-of-action>
    <toxicity>In rats subcutaneous administration of 250 to 500 times the recommended human dose, expressed on a per body weight basis, resulted in dyspnea, decreased activity, and local irritation at the injection site. There is no evidence at present that there is a clinical counterpart of this phenomenon. In early clinical trials with leuprolide acetate doses as high as 20 mg/day for up to two years caused no adverse effects differing from those observed with the 1 mg/day dose.</toxicity>
    <biotransformation>Primarily degraded by peptidase and not by cytochrome P450 enzymes.</biotransformation>
    <absorption>Bioavailability by subcutaneous administration is comparable to that by intravenous administration.</absorption>
    <half-life>~3 hours</half-life>
    <protein-binding>43% to 49%</protein-binding>
    <route-of-elimination>Excretion in urine</route-of-elimination>
    <volume-of-distribution>* 27 L [intravenous bolus administration to healthy male volunteers]</volume-of-distribution>
    <clearance>* 8.34 L/h [healthy male receiving a 1-mg IV bolus]</clearance>
    <secondary-accession-numbers>
      <secondary-accession-number>BIOD00009</secondary-accession-number>
      <secondary-accession-number>BTD00009</secondary-accession-number>
    </secondary-accession-numbers>
    <groups>
      <group>approved</group>
    </groups>
    <taxonomy>
      <kingdom></kingdom>
      <substructures/>
    </taxonomy>
    <synonyms>
      <synonym>Leuprorelin</synonym>
    </synonyms>
    <salts>
      <salt>Leuprolide acetate</salt>
      <salt>Leuprorelin acetate</salt>
    </salts>
    <brands>
      <brand>Eligard</brand>
      <brand>Enantone</brand>
      <brand>Leuplin</brand>
      <brand>LeuProMaxx</brand>
      <brand>Leupromer</brand>
      <brand>Lupron</brand>
      <brand>Lutrate</brand>
      <brand>Memryte</brand>
      <brand>Prostap 3</brand>
      <brand>Prostap SR</brand>
      <brand>Viadur</brand>
    </brands>
    <mixtures/>
    <packagers>
      <packager>
        <name>Abbott Laboratories Ltd.</name>
        <url>http://www.abbott.com</url>
      </packager>
      <packager>
        <name>Cardinal Health</name>
        <url>http://www.cardinal.com</url>
      </packager>
      <packager>
        <name>Eon Labs</name>
        <url></url>
      </packager>
      <packager>
        <name>Hospira Inc.</name>
        <url>http://www.hospira.com</url>
      </packager>
      <packager>
        <name>Oso Biopharmaceuticals Manufacturing LLC</name>
        <url></url>
      </packager>
      <packager>
        <name>Physicians Total Care Inc.</name>
        <url>http://www.physicianstotalcare.com</url>
      </packager>
      <packager>
        <name>Sanofi-Aventis Inc.</name>
        <url>http://www.sanofi-aventis.com</url>
      </packager>
      <packager>
        <name>Sun Pharmaceutical Industries Ltd.</name>
        <url>http://www.sunpharma.com</url>
      </packager>
      <packager>
        <name>Takeda Pharmaceutical Co. Ltd.</name>
        <url>http://www.takeda.com</url>
      </packager>
      <packager>
        <name>Teva Pharmaceutical Industries Ltd.</name>
        <url>http://www.tevapharm.com</url>
      </packager>
      <packager>
        <name>Tolmar Inc.</name>
        <url>http://www.tolmar.com</url>
      </packager>
    </packagers>
    <manufacturers/>
    <prices>
      <price>
        <description>Leuprolide 2wk 1 mg/0.2 ml kit</description>
        <cost currency="USD">385.33</cost>
        <unit>kit</unit>
      </price>
      <price>
        <description>Leuprolide Acetate 1 mg/0.2ml Kit 2.8ml 2-Week Kit</description>
        <cost currency="USD">400.74</cost>
        <unit>box</unit>
      </price>
      <price>
        <description>Eligard 7.5 mg syringe</description>
        <cost currency="USD">493.2</cost>
        <unit>syringe</unit>
      </price>
      <price>
        <description>Lupron 2-wk 1 mg/0.2 ml kit</description>
        <cost currency="USD">594.37</cost>
        <unit>kit</unit>
      </price>
      <price>
        <description>Eligard 22.5 mg syringe</description>
        <cost currency="USD">1479.6</cost>
        <unit>syringe</unit>
      </price>
      <price>
        <description>Eligard 30 mg syringe</description>
        <cost currency="USD">1972.8</cost>
        <unit>syringe</unit>
      </price>
      <price>
        <description>Eligard 45 mg syringe</description>
        <cost currency="USD">2959.2</cost>
        <unit>syringe</unit>
      </price>
    </prices>
    <categories>
      <category>Antineoplastic Agents</category>
      <category>Anti-Estrogen Agents</category>
    </categories>
    <affected-organisms>
      <affected-organism>Humans and other mammals</affected-organism>
    </affected-organisms>
    <dosages>
      <dosage>
        <form>Liquid</form>
        <route>Subcutaneous</route>
        <strength></strength>
      </dosage>
      <dosage>
        <form>Suspension, extended release</form>
        <route>Intramuscular</route>
        <strength></strength>
      </dosage>
      <dosage>
        <form>Suspension, extended release</form>
        <route>Subcutaneous</route>
        <strength></strength>
      </dosage>
    </dosages>
    <atc-codes>
      <atc-code>L02AE02</atc-code>
    </atc-codes>
    <ahfs-codes>
      <ahfs-code>10:00.00</ahfs-code>
    </ahfs-codes>
    <patents/>
    <food-interactions/>
    <drug-interactions/>
    <protein-sequences>
      <protein-sequence>
        <header>Leuprolide</header>
        <chain>PHWSYLLR</chain>
      </protein-sequence>
    </protein-sequences>
    <experimental-properties>
      <property>
        <kind>logP/hydrophobicity</kind>
        <value>0.1</value>
        <source></source>
      </property>
      <property>
        <kind>Molecular Weight</kind>
        <value>1209.3983</value>
        <source></source>
      </property>
      <property>
        <kind>Molecular Formula</kind>
        <value>C59H84N16O12</value>
        <source></source>
      </property>
    </experimental-properties>
    <external-identifiers>
      <external-identifier>
        <resource>ChEBI</resource>
        <identifier>6427</identifier>
      </external-identifier>
      <external-identifier>
        <resource>KEGG Compound</resource>
        <identifier>C07612</identifier>
      </external-identifier>
      <external-identifier>
        <resource>KEGG Drug</resource>
        <identifier>D08113</identifier>
      </external-identifier>
      <external-identifier>
        <resource>National Drug Code Directory</resource>
        <identifier>0024-0793-75</identifier>
      </external-identifier>
      <external-identifier>
        <resource>PharmGKB</resource>
        <identifier>PA450202</identifier>
      </external-identifier>
    </external-identifiers>
    <external-links>
      <external-link>
        <resource>Wikipedia</resource>
        <url>http://en.wikipedia.org/wiki/Leuprolide</url>
      </external-link>
      <external-link>
        <resource>RxList</resource>
        <url>http://www.rxlist.com/cgi/generic/eligard.htm</url>
      </external-link>
      <external-link>
        <resource>Drugs.com</resource>
        <url>http://www.drugs.com/cdi/leuprolide.html</url>
      </external-link>
    </external-links>
    <targets>
      <target partner="226">
        <actions>
          <action>agonist</action>
        </actions>
        <references># Castellon E, Clementi M, Hitschfeld C, Sanchez C, Benitez D, Saenz L, Contreras H, Huidobro C: Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma. Cancer Invest. 2006 Apr-May;24(3):261-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16809153&#xD;
# Borroni R, Di Blasio AM, Gaffuri B, Santorsola R, Busacca M, Vigano P, Vignali M: Expression of GnRH receptor gene in human ectopic endometrial cells and inhibition of their proliferation by leuprolide acetate. Mol Cell Endocrinol. 2000 Jan 25;159(1-2):37-43. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10687850&#xD;
# Imai A, Takagi A, Horibe S, Takagi H, Tamaya T: Fas and Fas ligand system may mediate antiproliferative activity of gonadotropin-releasing hormone receptor in endometrial cancer cells. Int J Oncol. 1998 Jul;13(1):97-100. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9625809&#xD;
# Murase M, Uemura T, Gao M, Inada M, Funabashi T, Hirahara F: GnRH antagonist-induced down-regulation of the mRNA expression of pituitary receptors: comparisons with GnRH agonist effects. Endocr J. 2005 Feb;52(1):131-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15758569&#xD;
# Khurana KK, Singh SB, Tatum AH, Schulz V, Badawy SZ: Maintenance of increased Bcl-2 expression in uterine leiomyomas after GnRH agonist therapy. J Reprod Med. 1999 Jun;44(6):487-92. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10394541</references>
        <known-action>yes</known-action>
      </target>
    </targets>
    <enzymes/>
    <transporters/>
    <carriers/>
  </drug>
  <drug type="biotech" created="2005-06-13 07:24:05 -0600" updated="2010-09-29 14:34:47 -0600" version="3.0">
    <drugbank-id>DB00008</drugbank-id>
    <name>Peginterferon alfa-2a</name>
    <description>Human interferon 2a, is a covalent conjugate of recombinant alfa-2a interferon with a single branched bis-monomethoxy polyethylene glycol (PEG) chain. The PEG moiety is linked at a single site to the interferon alfa moiety via a stable amide bond to lysine. Peginterferon alfa-2a has an approximate molecular weight of 60,000 daltons. Interferon alfa-2a is produced using recombinant DNA technology in which a cloned human leukocyte interferon gene is inserted into and expressed in Escherichia coli. The resultant protein is 165 amino acids. The PEG strand protects the molecule in vivo from proteolytic breakdown, substantially increases its in vivo half-life, and reduces immunogenicity by wrapping around and physically hindering access to the protein portion of the molecule.</description>
    <cas-number>198153-51-4</cas-number>
    <general-references></general-references>
    <synthesis-reference></synthesis-reference>
    <indication>For treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma.</indication>
    <pharmacology>Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R.</pharmacology>
    <mechanism-of-action>Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription) which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.</mechanism-of-action>
    <toxicity></toxicity>
    <biotransformation></biotransformation>
    <absorption></absorption>
    <half-life>Terminal half life is 80 hours (range 50 to 140 hours).</half-life>
    <protein-binding></protein-binding>
    <route-of-elimination></route-of-elimination>
    <volume-of-distribution></volume-of-distribution>
    <clearance></clearance>
    <secondary-accession-numbers>
      <secondary-accession-number>BIOD00043</secondary-accession-number>
      <secondary-accession-number>BTD00043</secondary-accession-number>
    </secondary-accession-numbers>
    <groups>
      <group>approved</group>
    </groups>
    <taxonomy>
      <kingdom></kingdom>
      <substructures/>
    </taxonomy>
    <synonyms/>
    <salts/>
    <brands>
      <brand>Pegasys</brand>
      <brand>Pegasys (Hoffman-La Roche Inc)</brand>
    </brands>
    <mixtures/>
    <packagers>
      <packager>
        <name>F Hoffmann La Roche Ltd.</name>
        <url>http://www.roche.com</url>
      </packager>
      <packager>
        <name>F Hoffmann-La Roche Ltd.</name>
        <url>http://www.roche.com</url>
      </packager>
    </packagers>
    <manufacturers/>
    <prices>
      <price>
        <description>Pegasys 180 mcg/ml vial</description>
        <cost currency="USD">642.64</cost>
        <unit>ml</unit>
      </price>
      <price>
        <description>Pegasys 180 mcg/0.5 ml conv.pk</description>
        <cost currency="USD">2533.2</cost>
        <unit>each</unit>
      </price>
      <price>
        <description>Pegasys (1 Kit = Four 180 mcg/ml Vials Prefilled Syringes) Box</description>
        <cost currency="USD">2634.53</cost>
        <unit>box</unit>
      </price>
    </prices>
    <categories>
      <category>Antineoplastic Agents</category>
      <category>Immunomodulatory Agents</category>
      <category>Antiviral Agents</category>
    </categories>
    <affected-organisms>
      <affected-organism>Humans and other mammals</affected-organism>
    </affected-organisms>
    <dosages>
      <dosage>
        <form>Solution</form>
        <route>Subcutaneous</route>
        <strength></strength>
      </dosage>
    </dosages>
    <atc-codes>
      <atc-code>L03AB11</atc-code>
    </atc-codes>
    <ahfs-codes>
      <ahfs-code>08:18.20</ahfs-code>
    </ahfs-codes>
    <patents>
      <patent>
        <number>2203480</number>
        <country>Canada</country>
        <approved>2009-06-30</approved>
        <expires>2017-04-23</expires>
      </patent>
      <patent>
        <number>2172664</number>
        <country>Canada</country>
        <approved>2000-10-03</approved>
        <expires>2016-03-26</expires>
      </patent>
    </patents>
    <food-interactions>
      <food-interaction>Recommended adequate hydration.</food-interaction>
    </food-interactions>
    <drug-interactions>
      <drug-interaction>
        <drug>DB01223</drug>
        <name>Aminophylline</name>
        <description>Interferon increases the effect and toxicity of theophylline</description>
      </drug-interaction>
      <drug-interaction>
        <drug>DB00651</drug>
        <name>Dyphylline</name>
        <description>Interferon increases the effect and toxicity of theophylline</description>
      </drug-interaction>
      <drug-interaction>
        <drug>DB01303</drug>
        <name>Oxtriphylline</name>
        <description>Interferon increases the effect and toxicity of theophylline</description>
      </drug-interaction>
      <drug-interaction>
        <drug>DB01265</drug>
        <name>Telbivudine</name>
        <description>Co-administration of Peginterferon alpha-2a and Telbivudine may increase the risk of serious peripheral neuropathy.</description>
      </drug-interaction>
      <drug-interaction>
        <drug>DB00277</drug>
        <name>Theophylline</name>
        <description>Interferon increases the effect and toxicity of theophylline</description>
      </drug-interaction>
    </drug-interactions>
    <protein-sequences>
      <protein-sequence>
        <header>DB00008 sequence</header>
        <chain>CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE</chain>
      </protein-sequence>
    </protein-sequences>
    <experimental-properties>
      <property>
        <kind>Molecular Weight</kind>
        <value>60000.0000</value>
        <source></source>
      </property>
    </experimental-properties>
    <external-identifiers>
      <external-identifier>
        <resource>Drugs Product Database (DPD)</resource>
        <identifier>2248077</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank</resource>
        <identifier>J00207</identifier>
      </external-identifier>
      <external-identifier>
        <resource>PharmGKB</resource>
        <identifier>PA10152</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P01563</identifier>
      </external-identifier>
    </external-identifiers>
    <external-links>
      <external-link>
        <resource>Wikipedia</resource>
        <url>http://en.wikipedia.org/wiki/Peginterferon_alfa-2a</url>
      </external-link>
      <external-link>
        <resource>RxList</resource>
        <url>http://www.rxlist.com/cgi/generic3/pegasys.htm</url>
      </external-link>
      <external-link>
        <resource>Drugs.com</resource>
        <url>http://www.drugs.com/cdi/peginterferon-alfa-2a.html</url>
      </external-link>
    </external-links>
    <targets>
      <target partner="428">
        <actions>
          <action>agonist</action>
        </actions>
        <references># Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15898717
# Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16953837
# Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. Epub 2009 Dec 3. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19955815
# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
        <known-action>yes</known-action>
      </target>
      <target partner="728">
        <actions>
          <action>agonist</action>
        </actions>
        <references># Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15898717
# Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16953837
# Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. Epub 2009 Dec 3. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19955815
# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
        <known-action>yes</known-action>
      </target>
    </targets>
    <enzymes/>
    <transporters/>
    <carriers/>
  </drug>
  <drug type="biotech" created="2005-06-13 07:24:05 -0600" updated="2010-09-29 14:34:47 -0600" version="3.0">
    <drugbank-id>DB00009</drugbank-id>
    <name>Alteplase</name>
    <description>Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells</description>
    <cas-number>105857-23-6</cas-number>
    <general-references></general-references>
    <synthesis-reference></synthesis-reference>
    <indication>For management of acute myocardial infarction, acute ischemic strok and for lysis of acute pulmonary emboli</indication>
    <pharmacology>Alteplase binds to fibrin in a thrombus and converts the entrapped plasminogen to plasmin. It also produces limited conversion of plasminogen in the absence of fibrin.</pharmacology>
    <mechanism-of-action>Alteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. </mechanism-of-action>
    <toxicity></toxicity>
    <biotransformation></biotransformation>
    <absorption></absorption>
    <half-life></half-life>
    <protein-binding></protein-binding>
    <route-of-elimination></route-of-elimination>
    <volume-of-distribution></volume-of-distribution>
    <clearance></clearance>
    <secondary-accession-numbers>
      <secondary-accession-number>BIOD00050</secondary-accession-number>
      <secondary-accession-number>BTD00050</secondary-accession-number>
    </secondary-accession-numbers>
    <groups>
      <group>approved</group>
    </groups>
    <taxonomy>
      <kingdom></kingdom>
      <substructures/>
    </taxonomy>
    <synonyms>
      <synonym>t-PA</synonym>
      <synonym>t-plasminogen activator</synonym>
      <synonym>Tissue-type plasminogen activator precursor</synonym>
      <synonym>tPA</synonym>
    </synonyms>
    <salts/>
    <brands>
      <brand>Activase (Genentech Inc)</brand>
    </brands>
    <mixtures/>
    <packagers>
      <packager>
        <name>Genentech Inc.</name>
        <url>http://www.gene.com</url>
      </packager>
    </packagers>
    <manufacturers/>
    <prices>
      <price>
        <description>Cathflo activase 2 mg vial</description>
        <cost currency="USD">106.33</cost>
        <unit>vial</unit>
      </price>
      <price>
        <description>Activase 50 mg vial</description>
        <cost currency="USD">2389.85</cost>
        <unit>vial</unit>
      </price>
      <price>
        <description>Activase 100 mg vial</description>
        <cost currency="USD">4779.71</cost>
        <unit>vial</unit>
      </price>
    </prices>
    <categories>
      <category>Thrombolytic Agents</category>
    </categories>
    <affected-organisms>
      <affected-organism>Humans and other mammals</affected-organism>
    </affected-organisms>
    <dosages>
      <dosage>
        <form>Powder, for solution</form>
        <route>Intravenous drip</route>
        <strength></strength>
      </dosage>
    </dosages>
    <atc-codes>
      <atc-code>S01XA13</atc-code>
      <atc-code>B01AD02</atc-code>
    </atc-codes>
    <ahfs-codes>
      <ahfs-code>20:12.20</ahfs-code>
    </ahfs-codes>
    <patents/>
    <food-interactions/>
    <drug-interactions>
      <drug-interaction>
        <drug>DB01381</drug>
        <name>Ginkgo biloba</name>
        <description>Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.</description>
      </drug-interaction>
      <drug-interaction>
        <drug>DB00727</drug>
        <name>Nitroglycerin</name>
        <description>IV nitroglycerin may decrease the effect of alteplase.</description>
      </drug-interaction>
      <drug-interaction>
        <drug>DB00208</drug>
        <name>Ticlopidine</name>
        <description>Increased bleeding risk. Monitor for signs of bleeding.</description>
      </drug-interaction>
    </drug-interactions>
    <protein-sequences>
      <protein-sequence>
        <header>DB00009 sequence</header>
        <chain>SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP</chain>
      </protein-sequence>
    </protein-sequences>
    <experimental-properties>
      <property>
        <kind>logP/hydrophobicity</kind>
        <value>-0.516</value>
        <source></source>
      </property>
      <property>
        <kind>Molecular Weight</kind>
        <value>59042.3000</value>
        <source></source>
      </property>
      <property>
        <kind>Molecular Formula</kind>
        <value>C2569H3928N746O781S40</value>
        <source></source>
      </property>
    </experimental-properties>
    <external-identifiers>
      <external-identifier>
        <resource>Drugs Product Database (DPD)</resource>
        <identifier>2245859</identifier>
      </external-identifier>
      <external-identifier>
        <resource>KEGG Drug</resource>
        <identifier>D02837</identifier>
      </external-identifier>
      <external-identifier>
        <resource>GenBank</resource>
        <identifier>L00153</identifier>
      </external-identifier>
      <external-identifier>
        <resource>PharmGKB</resource>
        <identifier>PA10012</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P00750</identifier>
      </external-identifier>
    </external-identifiers>
    <external-links>
      <external-link>
        <resource>Wikipedia</resource>
        <url>http://en.wikipedia.org/wiki/Alteplase</url>
      </external-link>
      <external-link>
        <resource>RxList</resource>
        <url>http://www.rxlist.com/cgi/generic/alteplas.htm</url>
      </external-link>
      <external-link>
        <resource>Drugs.com</resource>
        <url>http://www.drugs.com/cdi/alteplase.html</url>
      </external-link>
    </external-links>
    <targets>
      <target position="1" partner="234">
        <actions>
          <action>activator</action>
        </actions>
        <references># Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18673235
# Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A: Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009;5(1):249-56. Epub 2009 Apr 8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19436656
# Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17963464
# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
        <known-action>yes</known-action>
      </target>
      <target position="2" partner="595">
        <actions/>
        <references># Longstaff C, Williams S, Thelwell C: Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18673235
# Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A: Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009;5(1):249-56. Epub 2009 Apr 8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19436656
# Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17963464</references>
        <known-action>yes</known-action>
      </target>
      <target position="3" partner="791">
        <actions/>
        <references># Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284
# Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423</references>
        <known-action>unknown</known-action>
      </target>
      <target position="4" partner="267">
        <actions/>
        <references># Hilleman DE, Tsikouris JP, Seals AA, Marmur JD: Fibrinolytic agents for the management of ST-segment elevation myocardial infarction. Pharmacotherapy. 2007 Nov;27(11):1558-70. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17963464</references>
        <known-action>unknown</known-action>
      </target>
    </targets>
    <enzymes/>
    <transporters/>
    <carriers/>
  </drug>
</drugs>